

Regd. Office: 54-D, Kandivali Indl. Estate, Kandivali (West), Mumbai - 400 067. CIN: L24230MH1984PLC033389, website: www.makerslabs.com, e-mail: makers@makerslabs.com

THRU ONLINE FILING

May 22, 2023

BSE Ltd.
Phiroze Jeejeebhoy Towers
27th Floor, Dalal Street
Mumbai 400 023
Scrip Code: 506919

Dear Sirs,

- A. Pursuant to Regulation 33 and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the following which were taken on record at the Meeting of the Board of Directors of the Company held today at Mumbai:
 - (i) Audited Financial Results (Standalone) for the 4th quarter and financial year ended 31st March, 2023;
 - (ii) Report of the Auditors on the Audited Financial Results (Standalone) for the 4th guarter and financial year ended 31st March, 2023;
 - (iii) Audited Financial Results (Consolidated) for the financial year ended 31st March, 2023; and
 - (iv) Report of the Auditors on the Audited Financial Results (Consolidated) for the financial year ended 31st March, 2023.
- B. We are also enclosing herewith a declaration stating that the Audit Reports on the Standalone and Consolidated Financial Results for the financial year ended 31st March, 2023 are with unmodified opinion.

Kindly note that the Board meeting started at 11.00 a.m. and concluded at 1.20 p.m.

This is for your information and record.

Thanking you

Yours faithfully For Makers Laboratories Limited

Surbhi Sharma Company Secretary ACS 66485

Encl: a/a



MAKERS Makers Laboratories Ltd.

Regd. Office: 54-D, Kandivali Indl. Estate, Kandivali (West), Mumbai - 400 067. CIN: L24230MH1984PLC033389, website: www.makerslabs.com, e-mail: makers@makerslabs.com

22nd May, 2023

BSE Ltd. Phiroze Jeejeebhoy Towers 27th Floor, Dalal Street Mumbai 400 023

Dear Sirs.

In compliance with the provisions of Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time and SEBI Circular No. Cir/CFD/CMD/56/2016 dated May 27, 2016, we hereby declare that the M/s. Natvarlal Vepari & Co., Statutory Auditors of the Company have issued Audit Report with unmodified opinion on the Audited Financial Statements of the Company for the financial year ended 31st March, 2023.

Yours faithfully

For Makers Laboratories Limited

Sandeep Kadam

Chief Financial Officer

For Makers Laboratories Limited

Surbhi Sharma

Company Secretary

Regd. Office: 54D, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067

CIN: L24230MH1984PLC033389

Tel:+91 22 28688544 E-mail: investors@makerslabs.com, Website: www.makerslabs.com

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2023

(All Figures are Rupees in Lacs unless otherwise stated)

Sr. No.	Particulars	Quarter Ended Year Ended				nded
140.		31.03.2023	31.12.2022	31.03.2022	31.03.2023	31.03.2022
		Reviewed	Reviewed	Reviewed	Audited	Audited
ı	Revenue from Operations	1,084.24	1,062.52	902.82	4,254.67	5,237.56
П	Other Income	17.94	13.54	8.34	113.73	84.81
101	Total income (i + II)	1,102.18	1,076.06	911.16	4,368.40	5,322.37
IV	Expenses:	-,				
	a) Cost of materials consumed	89.41	123.65	142.34	643.74	722.40
	b) Purchases of stock-in-trade	230.64	311.60	486.05	1,684.48	2,221.48
	c) Changes in inventories of finished goods,	332.08	335.51	(43.96)	401.48	(151.57
	work-in-progress and stock-in-trade					
	d) Employee benefits expense	172.29	178.35	173.82	744.78	815.65
	e) Finance Cost	28.18	40.29	39.55	138.05	167.54
	f) Depreciation and amortisation expense	65.50	66.38	47.16	239.88	190.70
	g) Other expenses	277.46	298.02	247.57	1,193.56	1,324.85
	Total Expenses (IV)	1,195.56	1,353.80	1,092.53	5,045.97	5,291.05
v	Profit / (Loss) before tax (III - IV)	(93.38)	(277.74)	(181.37)	(677.57)	31.32
٧ı	Tax Expense	(55.55)	(2)			
	Current Tax			(8.50)	-	-
	Short / Excess Provision of earlier years	1.54		3.29	1.54	3.29
	Deferred Tax (Asset) / Liability	(14.45)	(20.75)	(15.82)	(43.02)	10.85
VII	Net Profit / (Loss) after tax (V-VI)	(80.47)	(256.99)	(160.34)	(636.09)	17.18
	Other Comprehensive Income	(44)	,,	` 		
	Items that will not be reclassified subsequently to					
	profit or loss					
	(a) Actuarial gain and loss	(0.34)	(0.70)	(1.08)	(2.43)	5.28
	Tax Effect thereon	(0.0.7)	. (45)	- (3.4.2)		•
	(b) Fair Value change through Other Comprehensive	······································				
	Income	(0.30)	(0.70)	(0.17)	(2.45)	56.63
	Tax Effect thereon	0.03	0.08	(6.55)	0.28	(11.17
VIII	Other Comprehensive Income	(0.61)	(1.32)	(7.80)	(4.60)	50.74
IX	Total Comprehensive Income after tax (VII + VIII)	(81.08)	(258.31)	(168.14)	(640.69)	67.92
x	Paid-up equity share capital (Face value of Rs.10/-each)	590.04	590.04	491.70	590.04	491.70
ΧI	Other Equity				5,238.42	4,538.32
XII	Earnings per share (of Rs.10/- each) - Not annualised:			-	·	
	Basic & Diluted	(1.29)	(4.25)	(3.13)	(10.58)	0.34





Notes:

- 1 The above audited financial results as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on May 22,2023.
- 2 The financial statements are prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- During the quarter ended June 30,2022, in accordance with provisions of the Companies Act and other relevant laws, the Company offered its shareholders to subscribe to a right issue of 9,83,396 equity shares at an issue price of Rs. 150/- per share aggregating to Rs.1,475.09 lacs. The issue was fully subscribed. Basic and diluted earnings per share for the quarter ended March'23, Dec'22, March'22 and Year ended March'23 and March'22 have been adjusted appropriately for the bonus element in respect of rights issue in accordance with Ind AS 33.
- The Company has only one reportable segment viz. 'Pharmaceuticals' and as such there are no separate reportable segment as per Indian Accounting Standard "Operating Segment (Ind AS-108)"
- The figures of the quarter ended March 31, 2023 and March 31, 2022 are the balancing figures between the figures for the audited full financial year and year to date unaudited figures up to the third quarter of the respective financial years which were subjected to limited review by the statutory auditors.
- 6 Figures for the previous period have been regrouped to confirm to the figures of the current period.

By Order of the Board For Makers Laboratories Limited

Saahil Parikh
Wholetime Director & CEO
(DIN 00400079)

Place : Mumbai, Date : May 22,2023



Audited Standalone Statement of Assets and Liabilities as at March 31, 2023

(All Figures are Rupees in Lacs unless otherwise stated)

	IAN rigi	ires are Rupees in Lacs unie		
	Particulars	As at	As at	
		Mar 31, 2023	Mar 31, 2022	
		(Audited)	(Audited)	
ASSE				
	current Assets	3,882.82	2,807.16	
	Property, Plant & Equipment	3,002.02 1.13	894.04	
	Capital Work-in-Progress	154.98	180.66	
	Right Of Use Asset	6.93	5.81	
	Other Intangible Assets	3.24	5.61	
	Intangible Assets Under Development	5.24	-	
(1)	Financial Assets	. 2252.10	2,254.64	
	(i) Investments	2,252.19	0.24	
	(ii) Loans	- 75.59	69.74	
/L\	(iii) Others		200.53	
(n)	Other Non-current Assets	186.04 6,562.92	6,412.82	
(2) Curre	ent Assets	0,302.32	0,412.02	
	Inventories	819.54	1,218.96	
	Financial Assets	013.54	. 1,210.50	
(0)	(i) Investments	_	_	
		- 752.99	535.45	
	(ii) Trade receivables	0.86	4.70	
	(iii) Cash and Cash Equivalents (iv) Bank Balances other than (iii) above	6.78	8.85	
	• •	0.49	0.87	
	(v) Loans		77.78	
(-)	(vi) Others Current Tax Assets (Net)	60.09	77.76	
	• •			
(a)	Other Current Assets	275.41	288.72	
TOTA	LASSETS	1,916.16	2,135.33 8,548.15	
1014	IL AJJE13	8,479.08	0,340.13	
FOLII	TY & LIABILITIES			
EQUI				
	Equity Share Capital	590.04	491.70	
	Other Equity	5,238.42	4,538.32	
	Equity	5,828.46	5,030.02	
10181	Equity	3,020.40	3,030.02	
LIABILIT	IES .		,	
	current Liabilities			
	Financial Liabilities			
1-7	(i) Borrowings	238.89	268.68	
	(ii) Lease Liability	179.46	195.62	
	(iii) Other Financial Liabilities	100.00	133.02	
(h)	Provisions	21.08	20.04	
	Deferred Tax Liabilities (Net)	19.87	63.18	
	Other Non-current Liabilities	-	03.10	
(0)	Other Non-current datalities	559.30	547.52	
(2) Curre	nt Liabilities	333.30	347.32	
	Financial Liabilities			
(0)	(i) Borrowings	685.21	1,451.06	
	(ii) Lease Liability	16.15	24.39	
	(iii) Trade Payables	10.13	24.39	
	- Due to Micro, small and Medium enterprises	99.70	91.44	
	- Due to Others	359.03		
			307.89	
161	(iv) Other financial liabilities	508.45	604.30	
	Other Current Liabilities	262.09	324.05	
	Provisions	160.69	167.48	
(a)	Current Tax Liabilities (Net)	2.001.22	2 070 64	
	L EQUITY AND LIABILITIES	2,091.32 8,479.08	2,970.61	
			8,548.15	





Audited Standalone Cash Flow Statement for the year ended March 31, 2023

		es are Rupees in Lacs unles	Apr 21-Mar 22
		Apr 22-Mar 23	Apr 21-Ivial 22
	h Flow from Operating Activities	(677.57)	31.32
1)	Net profit before taxation and extraordinary item	(077.37)	31.32
	Adjustments for :	239.88	190.70
	Depreciation		6.13
	Bad debts w/off	17.53	16.14
	Assets Scrap loss	1.36	
	(Profit)/ Loss on sale of Property, Plant & Equipment	(1.13)	5.4
	Unwinding of Lease rent Income	(0.45)	(0.5)
	Unwinding of Lease rent Expenses	0.01	. 0.1
	Interest income	(5.92)	(3.6
	Dividend income	(52.54)	(52.5
	Interest expense	134.12	167.5
2)	Operating profit before working capital changes	(344.71)	360.6
	Decrease / (Increase) in inventories	399.42	(130.2
	Decrease / (increase) in Trade Receivables	(235.07)	177.1
	Decrease / (increase) in Other Financial assets	. 13.14	93.1
	Decrease / (increase) in Other assets	10.95	14.3
	Increase / (Decrease) in Trade Payables	47.68	(197.6
	Increase / (Decrease) in Other Financial liabilities	76.46	113.1
	Increase / (Decrease) in Other liabilities	(61.96)	303.8
	Increase / (Decrease) in Provisions	(8.18)	1.2
3)	Cash generated from operation	(102.27)	735.6
•	Income tax paid (net)	(40.03)	(55.2
	Net cash from operating activities	(142.30)	680.4
Cas	h Flow from Investing Activities	, ,	
	Purchase of Property, Plant & Equipment including capital WIP	(448.16)	(1,108.4
	& Intangibles	(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	(-/
	Proceeds from Sale of Plant, Property and Equipment	35.17	7.1
	Sale of Shares	33.17	167.8
		5.23	2.8
	Interest received	52.54	52.5
	Dividend received		
	Net cash from / (used in) investing activities	(355.22)	(878.0
Casi	h Flow from Financing Activities	4 475 00	
	Proceeds from issue of shares (including securities premium)	1,475.09	
	Share issue expenses	(35.96)	
	Proceeds/ (Repayment) from short term borrowing (Net)	178.52	595.4
	Repayment of Non-Current borrowing	(284.16)	(245.2
	Intercorporate deposit repaid	(890.00)	
	Intercorporate deposit received	200.00	
	Payment of lease Liability	•	
	- Interest	(21.60)	(23.5
	- Principal	(12.67)	(9.0
	Interest paid	(115.54)	(140.7
	Net cash from / (used in) financing activities	493.68	176.8
Net	increase / (decrease) in cash and cash equivalents (A + B + C)	(3.84)	(20.8
	h and cash equivalents at beginning of year.	4.70	25.5
	h and cash equivalents at end of year	0.86	4.7
	nponents of Cash & Cash equivalents :		
	h and cheques on hand	0.46	0.8
	ince with banks	0.40	3.84
		0.86	4.70





CHARTERED ACCOUNTANTS

903-904, 9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: 6752 7100 Fax: 6752 7101 E-mail: nvc@nvc.in

Independent Auditor's Report on Audit of Annual Standalone Financial Results and Review of Quarterly Financial Results

To The Board of Directors of Makers Laboratories Limited

Opinion and Conclusion

We have

- a. Audited the Standalone Financial Results for the year ended March 31, 2023 and
- b. Reviewed the Standalone Financial Results for the quarter ended March 31, 2023 (refer 'Other Matters' section below), which were subject to limited review by us,

both included in the accompanying "Statement of Standalone Financial Results for the quarter and year Ended March 31, 2023." of Makers Laboratories Limited ("the Company"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations")

(a) Opinion on Annual Standalone Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2023:

- i. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net loss and total comprehensive loss and other financial information of the Company for the year then ended.

(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2023

With respect to the Standalone Financial Results for the quarter ended March 31, 2023, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2023, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be



CHARTERED ACCOUNTANTS

903-904, 9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: 6752 7100 Fax: 6752 7101 E-mail: nvc@nvc.in

disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2023

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2023 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Statement

This Statement, which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2023 have been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2023 that give a true and fair view of the net loss and other comprehensive loss and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether



CHARTERED ACCOUNTANTS

903-904, 9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: 6752 7100 Fax: 6752 7101 E-mail: nvc@nvc.in

due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors is responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors of the Company is also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities

(a) Audit of the Standalone Financial Results for the year ended March 31, 2023

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2023 as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.



CHARTERED ACCOUNTANTS

903-904, 9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: 6752 7100 Fax: 6752 7101 E-mail: nvc@nvc.in

- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the Company to express an opinion on the Annual Standalone Financial Results.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



CHARTERED ACCOUNTANTS

903-904, 9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: 6752 7100 Fax: 6752 7101 E-mail: nvc@nvc.in

(b) Review of the Standalone Financial Results for the quarter ended March 31, 2023

We conducted our review of the Standalone Financial Results for the quarter ended March 31, 2023 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Other Matters

The Statement includes the results for the quarter ended March 31,2023 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report on the Statement is not modified in respect of this matter.

AL VEPA

Mumbai

For Natvarlal Vepari & Co Chartered Accountants Firm Registration No. 106971W

Nuzhat Khan

Partner

M. No. 124960

Mumbai, Dated: - May 22, 2023

UDIN: 23124960BGVGDK 1280

Regd. Office: 54D, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067
CIN: L24230MH1984PLC033389

Tel:+91 22 28688544 E-mail : investors@makerslabs.com , Website : www.makerslabs.com

Statement of Audited Consolidated Financial Results for Quarter and Year Ended March 31, 2023

(All Figures are Rupees in Lacs unless otherwise stated)

				(All Figures are K	upees in Lacs unless	
			Quarter Ended		Year Ended	Year Ended
Sr. No.	Particulars	31.03.2023	31.12.2022	31.03.2022	31.03.2023	31.03.2022
110.		Reviewed	Reviewed	Reviewed	Audited	Audited
Li	Revenue from Operations	2,944.84	1,987.61	2,729.39	10,127.78	12,720.17
l ii	Other Income	12.11	26.61	64.53	227.60	260.43
	Total Income (I + II)	2,956.95	2,014.22	2,793.92	10,355.38	12,980.60
l iv	Expenses:					
'*		490.94	570.17	360.99	2,877.23	2,969.88
	a) Cost of materials consumed	230.63	311.60	486.05	1,684.47	2,221.48
-	b) Purchases of stock-in-trade		(331.22)	302.26	(493.59)	56.74
İ	c) Changes in inventories of finished goods,	806.63	(331.22)	302.20	(133.33)	
1	work-in-progress and stock-in-trade		202.07	317.64	1,173.08	1,251.06
1	d) Employee benefits expense	288.78	. 293.97		212.10	167.85
	e) Finance Cost	24.59	42.01	40.53		402.35
	f) Depreciation and amortisation expense	113.11	118.80	99.07	424.17	
	g) Other expenses	949.79	1,160.46	1,058.26	4,561.77	4,343.16
	Total Expenses (IV)	2,904.47	2,165.79	2,664.80	10,439.23	11,412.52
l v	Profit/ (Loss) Before exceptional items and Tax (III-IV)	52.48	(151.57)	129.12	(83.85)	1,568.08
VI	Exceptional Items income/ (expenses)			(2.94)		0.75
VII	Profit/ (Loss) Before Tax (V+VI)	52.48	(151.57)	126.18	(83.85)	1,568.83
VIII	Tax Expense					
	Current Tax	31.50	41.65	77.16	180.37	441.26
	Short /(Excess) Provision of earlier years	1.54		(20.51)	1.54	(20.51)
	Deferred Tax (Asset) / Liability	(15.12)	(15.87)	(23.43)	(46.61)	(23.65)
	Net Profit / (Loss) after tax but before non-controlling interests(VII-				(2.2.2.2)	4 474 77
IX	VIII)	34.56	(177.35)	92.96	(219.15)	1,171.73
x	Less: Share of non-controlling interests	(62.70)	(43.43)	(153.90)	(255.93)	(673.89)
ΧI	Net Profit / (Loss) after share of non-controlling interests (IX-X)	(28.14)	(220.78)	(60.94)	(475.08)	497.84
XII	Other Comprehensive Income	(3.42)	3.74	(12.47)	3.37	(4.85)
	(a) rietasiisi gairi (isaa)	2.22	(1.07)	2.96	-	2.63
	Tax Effect thereon			`	(2.45)	
	(b) Fair Value change through Other Comprehensive Income	(0.31)	(0.69)	(0.17)	(2.45)	56.63
	Tax Effect thereon	0.03	0.08	(6.55)	0.28	(11.17)
	Other Comprehensive Income / (Loss) for the period, net of tax	(1.48)	2.06	(16.23)	1.20	43.24
	7-15	33.08	(175.29)	76.73	(217.95)	1,214.97
XIII	Total Comprehensive Income after tax (IX + XII)	33.08	(173.23)		(227.53)	2,22 1137
	Profit for the period attributable to :					
	Owners of the parent	(28.14)	(220.78)	(60.94)	(475.08)	497.84
	Non-controlling interest - profit / (loss)	62.70	43.43	153.90	255.93	673.89
		34.56	(177.35)	92.96	(219.15)	1,171.73
	Other Comprehensive Income for the period attributable to :					
1		10.001	0.33	(11 (2)	(1.96)	47.33
1	Owners of the parent	(1.01)	0.22	(11.63)	3.16	(4.09)
	Non-controlling interest - profit / (loss)	(0.47)	1.84	(4.60)		
		(1.48)	2.06	(16.23)	1.20	43.24
	Total Comprehensive Income for the period attributable to :					
1	Owners of the parent	(29.15)	(220.56)	(72.57)	(477.04)	545.17
	Non-controlling interest - profit / (loss)	62.23	45.27	149.30	259.09	669.80
	14041-COLLCOHING INTELEST - PROJECT (1022)	33.08	(175.29)	76.73	(217.95)	1,214.97
		33.08	(273.23)		\	
xıv	Paid-up equity share capital (Face value of Rs.10/- each)	590.04	590.04	491.70	590.04	491.70
XV	Other Equity	350.04	330.04	7,52.70	6,330.09	5,466.34
XVI	Earnings per share (of Rs.10/- each) - Not annualised :				1 2,223.03	
^*'	Basic & Diluted	(0.43)	(3.65)	(1.19)	(7.90)	9.71
		<u> </u>				





Notes:

- 1 The above audited financial results as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on May 22,2023.
- The financial statements are prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- During the quarter ended June 30,2022, in accordance with provisions of the Companies Act and other relevant laws, the Holding Company offered its shareholders to subscribe to a right issue of 9,83,395 equity shares at an issue price of Rs. 150/- per share aggregating to Rs.1,475.09 lacs. The issue was fully subscribed. Basic and diluted earnings per share for the quarter ended March'23, Dec'22, March'22 and Year ended March'23 and March'24 have been adjusted appropriately for the bonus element in respect of rights issue in accordance with Ind AS 33.
- 4 Pursuant to acquisition of Resonance, the group has two reportable segments viz. "Pharmaceutical" and " Chemical Manufacturing" as per Indian Accounting Standard "Operating Segment (Ind AS- 108). Segment information is given here in below:

(All Figures are Rupees in Lacs)

				(All Figures are Aupees in Lacs)		
Particulars	Quarter Ended March 31, 2023	Quarter Ended Dec 31, 2022	Quarter Ended March 31, 2022	Year Ended March 31, 2023	Year Ended March 31, 2022	
Segment Revenue						
- Pharmaceutical	1,101.40	1,075.28	910.38	4,312.78	5,270.12	
- Chemical Manufacturing	1,855.55	938.94	1,883.54	6,042.60	7,710.48	
Segment Results - PBT						
- Pharmaceutical	(94.12)	(278.51)	(182.12)	(733.08)	(24.19	
- Chemical Manufacturing	146.60	126.94	308.30	649.23	1,593.02	
Total PBT	52.48	(151.57)	126.18	(83.85)	1,568.83	
Tax	(17.92)	(25.78)	(33.22)	(135.30)	(397.10	
Total PAT	34.56	(177.35)	92.96	(219.15)	1,171.73	
Segment Assets						
- Pharmaceutical				6,234.68	6,303.75	
- Chemical Manufacturing				8,994.82	8,129.55	
Segment Liabilities						
- Pharmaceutical				2,652.07	3,519.58	
- Chemical Manufacturing				1,609.96	1,104.49	

- 5 The figures of the quarter ended March 31, 2023 and March 31, 2022 are the balancing figures between the figures for the audited full financial year and year to date unaudited figures up to the third quarter of the respective financial years which were subjected to limited review by the statutory auditors.
- 6 Figures for the previous period have been regrouped to confirm to the figures of the current period's classification.

- 1

ATO

Saabil Parikh oletime Director & CEO (DIN 00400079)

By Order of the Board

Place : Mumbai, Date: May 22, 2023



Audited Consolidated Statement of Assets And Liabilities As At March 31, 2023

(All Figures are Rupees in Lacs unless otherwise stated)

	(All Figures are Rupees in Lacs unless otherwise stated As at As at				
	Particulars	Mar 31, 2023	Mar 31, 2022		
		(Audited)	(Audited)		
ASSET:	•				
(1) Non-cı	arrent Assets				
(a) F	Property, Plant & Equipment	8,228.49	6,626.08		
- (b) (Capital Work-in-Progress	45.36	938.44		
(c) F	Right Of Use Asset	154.98	180.66		
(d) (Other Intangible Assets	68.89	22.82		
(e) I	ntangible Assets Under Development	3.24	•		
(f) F	inancial Assets		•		
(i) Investments	7.78	22.08		
(ii) Loans	•	0.24		
(iii) Others	145.68	140.84		
(g) (Other Non-current Assets	241.42	211.08		
		8,895.84	8,142.24		
2) Curren					
(a) I	nventories .	3,132.10	2,384.39		
(b) F	inancial Assets				
(i) Investments		-		
(ii) Trade receivables	1,986.72	1,355.47		
(iii) Cash and Cash Equivalents	72.24	230.85		
(iv) Bank Balances other than (iii) above	364.66	636.20		
(v) Loans	0.49	1,000.87		
(vi) Others	61.04	81.78		
(c) (Current Tax Assets (Net)	8.41			
(d) (Other Current Assets	708.00	601.50		
		6,333.66	6,291.06		
TOTAL	ASSETS	15,229.50	14,433.30		
FOUIT	Y & LIABILITIES				
EQUIT					
	Equity Share Capital	590.04	491.70		
	Other Equity	6,330.09	5,466.34		
	attributable to the shareholders of the Holding company	6,920.13	5,958.04		
	In Controlling Interest	- 4,047.34	- 3,851.19		
ľ	Non Controlling Interest	4,047.34	3,831,13		
LIABILI	TIES				
(1) Non-cı	urrent Liabilities				
(a) F	inancial Liabilities				
(i) Borrowings	431.82	268.68		
(ii) Lease Liability	179.46	194.49		
	iii) Other Financial Liabilities	100.00	-		
(b) F	Provisions	26.80	43.05		
	Deferred Tax Liabilities (Net)	770.20	817.09		
	Other Non-current Liabilities	-	-		
, ,		1,508.28	1,323.31		
2) Curren	t Liabilities				
(a) F	inancial Liabilities				
	(i) Borrowings	714.12	1,451.06		
(ii) Lease Liability	16.14	25.51		
	ii) Trade Payables	•	-		
	- Due to Micro, small and Medium enterprises	124.42	153.87		
	- Due to Others	889.56	392.20		
	iv) Other financial liabilities	550.33	677.44		
-	Other Current Liabilities	274.28	391.39		
• •	Provisions	184.90	190.54		
	Current Tax Liabilities (Net)	-	18.75		
1-1		2,753.75	3,300.76		
	EQUITY AND LIABILITIES	15,229.50	14,433.30		





MAKERS LABORATORIES LIMITED.

Audited Consolidated Cash Flow Statement for the year ended March 31, 2023

(All Figures are Rupees in Lacs unless otherwise stated)

	Particulars	upees in Lacs unless othe 2022-23	2021-22
	sh Flow from Operating Activities	(00.05)	4.550.0
1)	Net profit before taxation and extraordinary item	(83.85)	1,568.8
	Adjustments for :	404.47	402.2
	Depreciation	424.17	402.3
	(Profit)/ Loss on sale of Property, Plant & Equipment	(1.77)	5.1
	(Profit)/Loss on sale of Mutual funds	(0.07)	(6.8
	Assets Scrapped	1.36	16.1
	Bad debts w/off	17.53	6.1
	Unwinding of Lease rent Income	(0.33)	(0.4
	Unwinding of Lease rent Expenses	0.01	0.1
	Interest income	(87.87)	(74.9
	Dividend income	(0.04)	(0.0
	Interest expense	212.10	173.2
		481.24	2,089.7
2)	Operating profit before working capital changes	(242.74)	262.2
	Decrease / (Increase) in inventories	(747.71)	362.2
	Decrease / (increase) in Trade Receivables	(648.80)	299.2
	Decrease / (increase) in Other Financial assets	13.56	91.7
	Decrease / (increase) in Other assets	(110.10)	222.2
	Increase / (Decrease) in Trade Payables	456.18	(930.1
	Increase / (Decrease) in Other Financial liabilities	76.18	(62.4
	Increase / (Decrease) in Other liabilities	(117.11)	317.6
	Increase / (Decrease) in Provisions	(18.52)	22.8
3)	Cash generated from operation	(615.08)	. 2,413.1
	Income tax paid (net)	(246.90)	(563.3
	Net cash from operating activities	(861.98)	1,849.8
Cas	sh Flow from Investing Activities		
	Purchase of Property, Plant & Equipment including capital WIP & Intangibles	(1,290.73)	(988.8
	Proceeds from Sale of Plant, Property and Equipment	40.28	60.6
	Intercorpate loans (given)/repaid	1,000.00	(1,000.0
	Sale of Investments	•	167.8
	Sale of mutual funds	11.92	70.3
	Movement in other bank balances	272.92	(559.6
	Interest received	90.82	70.4
	Dividend received	0.04	0.0
	Net cash from / (used) in investing activities	125.25	(2,179.1
Car	sh Flow from Financing Activities	113.23	(2,1,3.2
Cas	Issue of Share	1,475.09	
	•	(35.96)	
	Share issue expenses	·	/160.0
	Interest paid	(190.00)	(160.9
	Proceeds/(Repayment) from short term borrowing	178.52	534.5
	Intercorporate deposit repaid	(890.00)	
	Intercorporate deposit received	200.00	
	Repayment of Non-Current borrowing	(284.16)	(245.2
	Proceeds from Non-Current borrowing	221.84	
	Payment of lease Liability	•	
	- Interest	(21.60)	(23.5
	- Principal ,	(12.67)	(9.0
	Dividend & dividend tax paid	(62.94)	(62.9
	Net cash from (used in) financing activities	578.12	32.8
Ne	t increase / (decrease) in cash and cash equivalents (A + B + C)	-	
Cas	sh and cash equivalents at beginning of year	(158.61)	(296.4
Cas	sh and cash equivalents at end of year	230.85	527.3
Co	mponents of Cash & Cash equivalents :	72.24	230.8
	sh and cheques on hand		
	ance with banks	0.60	1.3
	2.15	71.64	229.4
	LOK IIIE	72.24	230.8



CHARTERED ACCOUNTANTS

903-904, 9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: 6752 7100 Fax: 6752 7101 E-mail: nvc@nvc.in

Independent Auditor's Report on Audit of Annual Consolidated Financial Results and Review of Quarterly Financial Results

To The Board of Directors of Makers Laboratories Limited

Opinion and Conclusion

We have,

- a. Audited the Consolidated Financial Results for the year ended March 31, 2023
- Reviewed the Consolidated Financial Results for the quarter ended March 31, 2023 (refer 'Other Matters' section below), which were subject to limited review by us

both included in the accompanying "Statement of Consolidated Financial Results for the quarter and year ended March 31, 2023" of Makers Laboratories Limited (the "Parent") and its subsidiary (the Parent and its subsidiary together referred to as the "Group"), and its share of the net loss after tax and total comprehensive loss for the quarter and year ended March 31, 2023, (the "Statement") being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

(a) Opinion on Annual Consolidated Financial Results

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of the other auditors on financial information of subsidiary referred to in Other Matters section below, the Consolidated Financial Results for the year ended March 31, 2023:

- (i) includes the consolidated financial results of the Makers Laboratories Limited (Holding company) and Resonance Specialties Limited (Subsidiary)
- (ii) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated



CHARTERED ACCOUNTANTS

903-904, 9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: 6752 7100 Fax: 6752 7101 E-mail: nvc@nvc.in

net loss and consolidated total comprehensive loss and other financial information of the Group for the year ended March 31, 2023.

(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2023

With respect to the Consolidated Financial Results for the quarter ended March 31, 2023, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below and based on the consideration of the review reports of other auditors referred to in 'Other Matters' section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the quarter ended March 31, 2023, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2023

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2023 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in 'Other Matters' section below, is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Statement

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2023, has been compiled from the related audited consolidated financial statements. This



CHARTERED ACCOUNTANTS

903-904, 9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: 6752 7100 Fax: 6752 7101 E-mail: nvc@nvc.in

responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2023 that give a true and fair view of the consolidated net loss and consolidated other comprehensive loss and other financial information of the Group in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Boards of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent, as aforesaid.

In preparing the Consolidated Financial Results, the respective Boards of Directors of the companies included in the Group are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Boards of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities

(a) Audit of the Consolidated Financial Results for the year ended March 31, 2023

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2023 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the



CHARTERED ACCOUNTANTS

903-904, 9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: 6752 7100 Fax: 6752 7101 E-mail: nvc@nvc.in

aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.



Alaks.

CHARTERED ACCOUNTANTS

903-904, 9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: 6752 7100 Fax: 6752 7101 E-mail: nvc@nvc.in

Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Information of the entities within the Group to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of entities included in the Annual Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Annual Consolidated Financial Results, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.

We communicate with those charged with governance of the Parent and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Consolidated Financial Results for the quarter ended March 31, 2023

We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2023 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAL A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SA specified under section 143(10)



CHARTERED ACCOUNTANTS

903-904, 9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: 6752 7100 Fax: 6752 7101 E-mail: nvc@nvc.in

of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the entity as listed under paragraph (a)(i) of Opinion and Conclusion section above.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Other Matters

- a. We did not audit the financial statements of a subsidiary, Resonance Specialties Limited, whose financial statements reflect total assets of Rs. 6,579.37 Lacs as at March 31, 2023, total revenue of Rs. 6,042.71 lacs and net cash inflow amounting to Rs. (424.24) lacs for the year ended on that date, as considered in the preparation of the consolidated Ind AS financial statements. The said financial statements have been audited by their respective independent auditor whose reports have been furnished to us by the Management and our opinion on the consolidated Ind AS financial statements, in so far as it relates to the amounts and disclosures included in respect of this subsidiary is based solely on the reports of the other auditor and the procedures stated by us in paragraph above. Our opinion on the Consolidated Financial Statements, and our report on Other Legal and Regulatory Requirements below, is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditor.
- b. Attention is drawn to Note 5 to the Statement, which states that the consolidated financial results include the results for the quarter ended March 31, 2023, being balancing figure between audited figures in respect of the full year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report is not modified in respect of this matter.

Our report on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

For Natvarlal Vepari & Co

Chartered Accountants

Firm Registration No. 106971W

Nuzhat khan

Partner

M. No. 124960

Mumbai, Dated: - May 22, 2023

UDIN-23124960 BGVG DM 2758